Tofacitinib Improves Outcomes in Patients With Tough-to-Treat Rheumatoid Arthritis
By Jill Stein…
dgnews.docguide.com
Add-on tofacitinib as good as adalimumab for active RA
MADRID – Findings from phase IIIB/IV ORAL Strategy study verify the safety and effectiveness of tofacitinib as a non–tumor necrosis factor inhibitor treatment option.
mdedge.com
For difficult-to-treat RA, the better STRATEGY is to ADD-ON Tofacitinib to MTX, rather than to replace it.
Sure, Tofacitinib can be used alone (Oral SOLO), but it is only adequately effective in mild-to-moderate cases. If the RA is mild/moderate, why does one need to resort to expensive Tofacitinib in the first instance? Often, “MTX intolerance” is a relative luxury symptom.
Sure, Tofacitinib can be used alone (Oral SOLO), but it is only adequately effective in mild-to-moderate cases. If the RA is mild/moderate, why does one need to resort to expensive Tofacitinib in the first instance? Often, “MTX intolerance” is a relative luxury symptom.
Baricitinib Derailed by FDA Review
Eli Lilly and Co disclosed today that upon further discussions with the US Food and Drug Administration (FDA) there would be a delay in further regulatory decisions…
rheumnow.com
Filgotinib: Selective JAK1 inhibition shows promise in RA patients
The highly selective janus kinase 1 inhibitor filgotinib shows efficacy and has an encouraging safety profile in patients with rheumatoid arthritis and an inadequate response to methotrexate, say researchers who investigated the agent in two short…
medwirenews.com
Upadacitinib Effective in Rheumatoid Arthritis
AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in…
rheumnow.com
AbbVie’s Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis
NORTH CHICAGO, Ill., June 7, 2017 /PRNewswire/…
prnewswire.com
FDA sent similar drug for more clinical trials last spring
medpagetoday.com
When thrombosis was an issue with Baricitinib holding up FDA approval, and 1 of 2 deaths with Upadacitinib is due to pulmonary embolism, it’s more likely to be related than not.
